@phdthesis{Kessler2009,
  author    = {Keßler, Almuth Friederike},
  title     = {Der Proteasomenaktivator PA28gamma bei der Tumorentstehung und seine Verbindung zur Stresssignalgebung und zur Zellzyklusregulation},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-74469},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2009},
  abstract  = {Das Glioblastom ist der h{\"a}ufigste hirneigene Tumor des Erwachsenen. Es ist hoch invasiv, stark proliferierend und mit einer schlechten Prognose assoziiert. Heutige Therapiean-s{\"a}tze zielen, neben der m{\"o}glichst vollst{\"a}ndigen Resektion des Tumorgewebes, vor allem auf Apoptoseinduktion durch DNA-Sch{\"a}den in Tumorzellen. Daher ist die Aufkl{\"a}rung der molekularen Grundlagen dieser Prozesse essentiell, um Verbesserungen bei den Behandlungsm{\"o}glichkeiten erzielen zu k{\"o}nnen. Der Proteasomenaktivator PA28γ wird im Hirngewebe stark exprimiert, {\"u}ber seine Funktion ist jedoch nur wenig bekannt. Er wurde als Interaktionspartner des Zellzyklus- und DNA-Schadensregulators Mad2b in einem Hefe Two-Hybrid Screen identifiziert. Im Rahmen dieser Arbeit wurde diese Wechselwirkung mittels eines GST-Pulldown Experimentes be-st{\"a}tigt. Obwohl PA28γ in Verbindung mit der Zellproliferation gebracht wird, konnte in GBM-Zelllinien keine signifikante {\"A}nderung der Zellteilungsraten beobachtet werden. Allerdings unterst{\"u}tzte die vermehrte Expression von PA28γ die Apoptose. Um durch neue Interaktionspartner von PA28γ Hinweise auf dessen Funktion zu erhalten, wurde ein Hefe Two-Hybrid Screen durchgef{\"u}hrt: PA28gamma steuert den Abbau von p53 und verweist {\"u}ber die hier neu beschriebene Interaktion mit HIPK1 ebenfalls auf den programmierten Zelltod. Dieser pro-apoptotische Zusammen-hang wird unterst{\"u}tzt durch die Interaktion mit 1A6/DRIM-interacting protein. Die Inter-aktion der Sumo E2 Ligase Ubc9 mit PA28gamma war ein erster Hinweis f{\"u}r eine Sumoylierung des Proteasomenaktivators, die die PA28gamma Aktivit{\"a}t regulieren k{\"o}nnte. Gleichzeitig ist Ubc9, wie auch die E3-Ligase PIAS, im Zusammenhang mit Apoptose beschrieben worden. Diese Fragestellungen wurden in weiterf{\"u}hrenden Arbeiten erforscht. Einen anderen Aspekt beleuchtet die Interaktion von PA28gammamit Catenin alpha. Durch diese Wechselwirkung k{\"o}nnte PA28gamma Einfluß auf Interzellul{\"a}rkontakte nehmen. Gerade im Hin-blick auf das GBM, charakterisiert durch ausgepr{\"a}gtes Migrations- und Invasionsverhal-ten, k{\"o}nnte die Regulation von Interzellul{\"a}rkontakten von besonderer Bedeutung sein. Aufgrund der oben beschriebenen Eigenschaften von PA28gammasollte dieses Protein f{\"u}r eine Therapie mittels DNA-Sch{\"a}den induzierter Apoptose erforscht werden. PA28gamma k{\"o}nnte bei diesen Vorg{\"a}ngen ein zentraler Faktor sein, dessen Manipulation die etablierten Therapieformen unterst{\"u}tzen und deren Wirkung verbessern.},
  subject      = {Proteasomenaktivator},
  language  = {de}
}
@article{HagemannKesslerWiesneretal.2014,
  author    = {Hagemann, Carsten and Kessler, Almuth Friederike and Wiesner, Miriam and Denner, Joachim and K{\"a}mmerer, Ulrike and Vince, Giles Hamilton and Linsenmann, Thomas and L{\"o}hr, Mario and Ernestus, Ralf-Ingo},
  title     = {Expression-analysis of the human endogenous retrovirus HERV-K in human astrocytic tumors},
  doi       = {10.1186/1756-0500-7-159},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-110211},
  year      = {2014},
  abstract  = {Background The human endogenous retrovirus K (HERV-K) has been acquired by the genome of human ancestors million years ago. It is the most complete of the HERVs with transcriptionally active gag, pol and env genes. Splice variants of env, which are rec, 1.5 kb transcript and Np9 have been suggested to be tumorigenic. Transcripts of HERV-K have been detected in a multitude of human cancers. However, no such reports are available concerning glioblastomas (GBM), the most common malignant brain tumor in adults. Patients have a limited prognosis of 14.6 months in median, despite standard treatment. Therefore, we elucidated whether HERV-K transcripts could be detected in these tumors and serve as new molecular target for treatment. Findings We analyzed human GBM cell lines, tissue samples from patients and primary cell cultures of different passages for HERV-K full length mRNA and env, rec and 1.5 kb transcripts. While the GBM cell lines U138, U251, U343 and GaMG displayed weak and U87 strong expression of the full length HERV-K, the splice products could not be detected, despite a weak expression of env mRNA in U87 cells. Very few tissue samples from patients showed weak expression of env mRNA, but none of the rec or 1.5 kb transcripts. Primary cells expressed the 1.5 kb transcript weakly in early passages, but lost HERV-K expression with extended culture time. Conclusions These data suggest that HERV-K splice products do not play a role in human malignant gliomas and therefore, are not suitable as targets for new therapy regimen.},
  language  = {en}
}
@article{DufnerKesslerJustetal.2022,
  author    = {Dufner, Vera and Kessler, Almuth Friederike and Just, Larissa and Hau, Peter and Bumes, Elisabeth and Pels, Hendrik Johannes and Grauer, Oliver Martin and Wiese, Bettina and L{\"o}hr, Mario and Jordan, Karin and Strik, Herwig},
  title     = {The emesis trial: depressive glioma patients are more affected by chemotherapy-induced nausea and vomiting},
  series = {Frontiers in Neurology},
  volume    = {13},
  journal   = {Frontiers in Neurology},
  issn      = {1664-2295},
  doi       = {10.3389/fneur.2022.773265},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-262859},
  year      = {2022},
  abstract  = {Purpose Glioma patients face a limited life expectancy and at the same time, they suffer from afflicting symptoms and undesired effects of tumor treatment. Apart from bone marrow suppression, standard chemotherapy with temozolomide causes nausea, emesis and loss of appetite. In this pilot study, we investigated how chemotherapy-induced nausea and vomiting (CINV) affects the patients' levels of depression and their quality of life. Methods In this prospective observational multicentre study (n = 87), nausea, emesis and loss of appetite were evaluated with an expanded MASCC questionnaire, covering 10 days during the first and the second cycle of chemotherapy. Quality of life was assessed with the EORTC QLQ-C30 and BN 20 questionnaire and levels of depression with the PHQ-9 inventory before and after the first and second cycle of chemotherapy. Results CINV affected a minor part of patients. If present, it reached its maximum at day 3 and decreased to baseline level not before day 8. Levels of depression increased significantly after the first cycle of chemotherapy, but decreased during the further course of treatment. Patients with higher levels of depression were more severely affected by CINV and showed a lower quality of life through all time-points. Conclusion We conclude that symptoms of depression should be perceived in advance and treated in order to avoid more severe side effects of tumor treatment. Additionally, in affected patients, delayed nausea was most prominent, pointing toward an activation of the NK1 receptor. We conclude that long acting antiemetics are necessary totreat temozolomide-induced nausea.},
  language  = {en}
}
@article{NicklEckGoedertetal.2023,
  author    = {Nickl, Vera and Eck, Juliana and Goedert, Nicolas and H{\"u}bner, Julian and Nerreter, Thomas and Hagemann, Carsten and Ernestus, Ralf-Ingo and Schulz, Tim and Nickl, Robert Carl and Keßler, Almuth Friederike and L{\"o}hr, Mario and Rosenwald, Andreas and Breun, Maria and Monoranu, Camelia Maria},
  title     = {Characterization and optimization of the tumor microenvironment in patient-derived organotypic slices and organoid models of glioblastoma},
  series = {Cancers},
  volume    = {15},
  journal   = {Cancers},
  number    = {10},
  issn      = {2072-6694},
  doi       = {10.3390/cancers15102698},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-319249},
  year      = {2023},
  abstract  = {While glioblastoma (GBM) is still challenging to treat, novel immunotherapeutic approaches have shown promising effects in preclinical settings. However, their clinical breakthrough is hampered by complex interactions of GBM with the tumor microenvironment (TME). Here, we present an analysis of TME composition in a patient-derived organoid model (PDO) as well as in organotypic slice cultures (OSC). To obtain a more realistic model for immunotherapeutic testing, we introduce an enhanced PDO model. We manufactured PDOs and OSCs from fresh tissue of GBM patients and analyzed the TME. Enhanced PDOs (ePDOs) were obtained via co-culture with PBMCs (peripheral blood mononuclear cells) and compared to normal PDOs (nPDOs) and PT (primary tissue). At first, we showed that TME was not sustained in PDOs after a short time of culture. In contrast, TME was largely maintained in OSCs. Unfortunately, OSCs can only be cultured for up to 9 days. Thus, we enhanced the TME in PDOs by co-culturing PDOs and PBMCs from healthy donors. These cellular TME patterns could be preserved until day 21. The ePDO approach could mirror the interaction of GBM, TME and immunotherapeutic agents and may consequently represent a realistic model for individual immunotherapeutic drug testing in the future.},
  language  = {en}
}